Aurinia Pharmaceuticals Inc. (AUPH) Price Target Analysis
Updated Jun 18, 2026
Analyst Rating: Buy
Based on 14 analysts23.5% Above Target
AUPH trades 23.5% above Wall Street's consensus target of $12.60.
Current Price$16.46
Average Target$12.60
Target
Current
Low$6.00
Median$13.00
High$16.00
Analyst Target Range
Forward P/E17.1x
(Fair)
PEG Ratio—
Implied Growth-55.7%
(Declining)
Analyst Spread79.4%
(Wide Disagreement)
Price Forecast (1 Year)
Last 12 months price action with 12-month analyst target path
Consensus Scenario Assumptions
The base valuation assumes AUPH achieves its forward estimates and maintains a stable P/E multiple of 17.1x. This scenario reflects the blended consensus of 14 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
AUPH Price Target Analysis
Updated June 22, 2026As of June 22, 2026, Aurinia Pharmaceuticals Inc. (AUPH) has a Wall Street consensus price target of $12.60, based on estimates from 14 covering analysts. With the stock currently trading at $16.46, this represents a potential downside of -23.5%. The company has a market capitalization of $2.12B.
Analyst price targets range from a low of $6.00 to a high of $16.00, representing a 79% spread in expectations. The median target of $13.00 aligns closely with the consensus average. The wide target spread reflects significant disagreement on fair value.
The current analyst consensus rating is Buy, with 11 analysts rating the stock as a Buy or Strong Buy,3 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, AUPH trades at a trailing P/E of 8.0x and forward P/E of 17.1x. Analysts expect EPS to grow -55.7% over the next year.
Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $5.67, with bear and bull scenarios of $3.57 and $7.46 respectively. Model confidence stands at 60/100, reflecting moderate uncertainty in projections.
Investment Context: Price targets represent analyst expectations for the next 12 months and should be considered alongside your own research. Targets are based on analysts' assumptions about earnings growth, margins, and market conditions which may change. For sector-specific context, view other Healthcare stocks.
Analyst Sentiment Comparison
Industry Peer AnalysisAvg Peer Upside
+49.6%
Industry Consensus
Avg Forward P/E
33.7x
(Growth Premium)
Peers with Coverage
10 / 10
Active Analyst Tracking
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 LGNDLigand Pharmaceuticals Incorporated | $5.5B | $274.88 | $265.33 | -3.5% | Buy | 30.3x | 17 |
 ANIPANI Pharmaceuticals, Inc. | $1.8B | $79.49 | $124.00 | +56.0% | Buy | 8.5x | 10 |
 PRAXPraxis Precision Medicines, Inc. | $8.2B | $282.31 | $584.00 | +106.9% | Buy | — | 16 |
 CORTCorcept Therapeutics Incorporated | $8.6B | $79.91 | $83.00 | +3.9% | Buy | 136.5x | 26 |
 GSKGSK plc | $101.9B | $50.67 | $52.45 | +3.5% | Hold | 14.0x | 29 |
 BIIBBiogen Inc. | $29.0B | $196.58 | $218.32 | +11.1% | Buy | 13.5x | 48 |
 ALNYAlnylam Pharmaceuticals, Inc. | $37.1B | $278.09 | $454.27 | +63.4% | Buy | 37.1x | 52 |
 VKTXViking Therapeutics, Inc. | $3.5B | $30.38 | $93.60 | +208.1% | Buy | — | 24 |
 IQVIQVIA Holdings Inc. | $28.5B | $167.77 | $219.44 | +30.8% | Buy | 13.1x | 44 |
 CRLCharles River Laboratories International, Inc. | $8.9B | $185.00 | $214.14 | +15.8% | Buy | 16.7x | 37 |
AUPH — Frequently Asked Questions
Quick answers to the most common questions about buying AUPH stock.
What is the AUPH stock price target for 2026?
AUPH's consensus price target is $12.6, -23.5% below the current price of $16.46. The 14 analysts tracking AUPH see downside risk at present valuations.
Is AUPH a buy, sell, or hold?
AUPH has a consensus rating of "Buy" based on 14 Wall Street analysts. The rating breakdown is predominantly bullish, with 11 Buy/Strong Buy ratings. The consensus 12-month price target of $12.6 implies -23.5% downside from current levels.
Is AUPH stock overvalued or undervalued?
With a forward P/E of 17.1458x, AUPH trades at a relatively low valuation. The consensus target of $12.6 implies -23.5% move, suggesting the market may be pricing in risks.
How high can AUPH stock go?
The most bullish Wall Street analyst has a price target of $16 for AUPH, while the most conservative target is $6. The consensus of $12.6 represents the median expectation. Our quantitative valuation model projects a bull case target of $7 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.
How many analysts cover AUPH stock?
AUPH is moderately covered, with 14 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 11 have Buy ratings, 3 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
What is the AUPH stock forecast?
The 12-month AUPH stock forecast based on 14 Wall Street analysts shows a consensus price target of $12.6, with estimates ranging from $6 (bear case) to $16 (bull case). The median consensus rating is "Buy". Our proprietary valuation model produces a base case fair value of $6, with bear/bull scenarios of $4/$7.
What is AUPH's fair value based on fundamentals?
Our quantitative valuation model calculates AUPH's fair value at $6 (base case), with a bear case of $4 and bull case of $7. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 60/100.
What is AUPH's forward P/E ratio?
AUPH trades at a forward P/E ratio of 17.1x based on next-twelve-months earnings estimates compared to a trailing P/E of 8.0x. The higher forward P/E suggests near-term earnings pressure. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Should I buy AUPH stock?
Analysts are cautious on AUPH, with 0 Sell ratings and a price target of $12.6 (-23.5% from current price). The "Buy" consensus suggests careful evaluation before buying. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
Why do AUPH price targets vary so much?
AUPH analyst price targets range from $6 to $16, a 79% wide spread indicating significant analyst disagreement. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $12.6 consensus represents the middle ground. Our model's $4-$7 range provides an independent fundamental perspective.
Consensus-Based Analysis Tools
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare